Grow and create a competitive advantage
The environment in which pharmaceutical and life sciences companies operate is being driven by an increasingly demanding healthcare agenda. The need for innovative, cost effective medicines continues to rise while payers, healthcare providers and patients are demanding greater value for money. Through a capabilities driven approach to strategy we are supporting companies to align their strategic direction to the core capabilities necessary to thrive in Canada’s evolving pharma market. From breakthrough commercial innovation to disciplined portfolio management, we are working with our clients to optimize their business models, form alliances and partnerships for sources of innovation, add value with beyond the pill services and develop outcomes evidence generation for today’s value driven environment.
A critical makeover for pharmaceutical companies: Overcoming industry obstacles with a cross-functional strategy
This is a difficult time for pharmaceutical companies — so difficult, in fact, that many are reconsidering their business models. The litany of concerns that pharmaceutical companies face includes payers tightening up on cost management, strained government healthcare budgets, the need to understand and adopt new technologies, and challenges to their traditional pricing mechanisms by empowered stakeholders, from patients to payers.
Compounding the external obstacles, however, is the internal culture of most pharma companies. This is an industry that has long operated through disparate components — silos that separated R&D, commercial, production, and supply chain. And, in turn, these walled-off parts of the organization have been disconnected from the external-facing parts, which are responsible for managing relationships with regulators, policymakers, the medical community, and the rest of the industry. These silos can obstruct patient access and breed inefficiency and waste. They affect drug approval time and pricing, influence support for specific drugs by theme.
Effectively manage your product lines, from initial innovation to sale
As a Canadian life sciences or pharmaceutical company, you know that managing the product pipeline is one of your biggest responsibilities. The road that most health-related products follow — from research and development and patent acquisition to regulatory compliance and finally commercialization — is long and full of pitfalls. Canadian players are especially vulnerable to pipeline jams, as our country's regulatory regime makes it hard for both large and small companies to reap the benefits from innovation.
Anticipating and combating threats to your product pipeline require targeted strategies.
Stimulate commercial innovation
Commercial leaders in the pharmaceutical and life sciences industry face a rapidly changing healthcare landscape. There are significant concerns about patent expirations, consolidating customers and the increased use of generics as well as other hurdles such as new regulations, greater scrutiny of pricing and value, healthcare cost trends and advancing technology. We can work with you to effectively manage these obstacles to ensure your organization remains stable and profitable. We help you to identify and frame the issues most relevant to your business and we partner with you to resolve those challenges. Our expertise in commercial strategy, operations and compliance creates high-impact recommendations that work in the real world.
Loss of Exclusivity
Patent expiry is no longer the end of the road for drug commercialization that it once was but rather a bend in the road during a drug’s lifespan. Successfully navigating that bend in the road of often a challenge for pharmaceutical companies because the approach and skill sets required for post-LOE commercial success are much different from when a product is commercialized under patent.
Focus for branded drug products is generally rooted in expanding reach as wide as possible and driving Rx volume as high as possible. Post-LOE strategy, on the other hand, is rooted in patient retention and focusing only on those segments where you know you can derive value long term.
At PwC, our post-LOE offering includes a framework to transition your team to view the market through a non-exclusivity lens. We’ll help you uncover multiple options for value delivery and patient retention that go beyond traditional card programs.
Through joint business relationships with a number of partners, we have exclusive access to patient-level and physician-level data sets. This supports scenario modelling that allows you to assess strategic options and the impact of various tactics with confidence.